{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:47:54Z","timestamp":1787784474316,"version":"build-2784847793"},"reference-count":55,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2018,7,2]]},"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of <jats:italic>BRCA1\/2<\/jats:italic>-related ovarian cancers has resulted in an increased demand and urgency for genetic testing results, while technological developments have led to widespread use of multi-gene cancer panels and development of tumour testing protocols. Traditional genetic counselling models are no longer sustainable and must evolve to match the rapid evolution of genetic testing technologies and developments in personalized medicine. Recently, representatives from oncology, clinical genetics, molecular genetics, pathology, and patient advocacy came together to create a national multi-disciplinary Canadian consortium. By aligning stakeholder interests, the BRCA Testing to Treatment (BRCA TtoT) Community of Practice aims to develop a national strategy for tumour and germline <jats:italic>BRCA1\/2<\/jats:italic> testing and genetic counselling in women with ovarian cancer. This article serves to provide an overview of the recent evolution of genetic assessment for <jats:italic>BRCA1\/2<\/jats:italic>-associated gynecologic malignancies and outline a Canadian roadmap to facilitate change, improve genetic testing rates, and ultimately improve outcomes for hereditary ovarian cancer patients and their families.<\/jats:p>","DOI":"10.1136\/jmedgenet-2018-105472","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T16:42:06Z","timestamp":1532450526000},"page":"571-577","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap"],"prefix":"10.1136","volume":"55","author":[{"given":"Jeanna M","family":"McCuaig","sequence":"first","affiliation":[{"name":"Familial Breast & Ovarian Cancer Clinic, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L","family":"Stockley","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory Genetics and Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fung-Kee-Fung","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon D","family":"Altman","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bentley","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nova Scotia Health Authority, Halifix, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Q","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Cormier","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universit\u00e9 de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Hirte","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kieser","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andree","family":"MacMillan","sequence":"additional","affiliation":[{"name":"Provincial Medical Genetics Program, Eastern Health, St John\u2019s, Newfoundland and Labrador, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S","family":"Meschino","sequence":"additional","affiliation":[{"name":"Department of Genetics, North York General Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Panabaker","sequence":"additional","affiliation":[{"name":"Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Perrier","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Alberta Children\u2019s Hospital, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universit\u00e9 de Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasmintan A","family":"Schrader","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Serfas","sequence":"additional","affiliation":[{"name":"Department of Genetics and Metabolism, Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tomiak","sequence":"additional","affiliation":[{"name":"Department of Genetics, Children\u2019s Hospital of Eastern Ontario, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, CIUSSS West-Central Montreal Jewish General Hospital, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Henri","family":"Gotlieb","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hoskins","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-8674","authenticated-orcid":false,"given":"Raymond H","family":"Kim","sequence":"additional","affiliation":[{"name":"Familial Breast & Ovarian Cancer Clinic, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"2025101710504963000_55.9.571.1","unstructured":"Canadian Cancer Society. Canadian cancer society\u2019s advisory committee on cancer statistics, canadian cancer statistics. Toronto, ON: Canadian Cancer Society, 2017."},{"key":"2025101710504963000_55.9.571.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"2025101710504963000_55.9.571.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.01.020"},{"key":"2025101710504963000_55.9.571.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115052108"},{"key":"2025101710504963000_55.9.571.5","doi-asserted-by":"crossref","unstructured":"Eoh KJ , Kim JE , Park HS , Lee ST , Park JS , Han JW , Lee JY , Kim S , Kim SW , Kim JH , Kim YT , Nam EJ . Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1\/2. Cancer Res Treat 2017.doi:10.4143\/crt.2017.220","DOI":"10.4143\/crt.2017.220"},{"key":"2025101710504963000_55.9.571.6","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31825f3576"},{"key":"2025101710504963000_55.9.571.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.05.003"},{"key":"2025101710504963000_55.9.571.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"2025101710504963000_55.9.571.9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025101710504963000_55.9.571.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112"},{"key":"2025101710504963000_55.9.571.11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2025101710504963000_55.9.571.12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.12.005","article-title":"Ovarian cancer in Lynch syndrome; a systematic review","volume":"55","author":"Helder-Woolderink","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025101710504963000_55.9.571.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2820"},{"key":"2025101710504963000_55.9.571.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"2025101710504963000_55.9.571.15","unstructured":"Government of Canada. Qualifying Notice for Lynparza. 2016 https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/lynparza-notice-compliance-conditions-qualifying-notice.html"},{"key":"2025101710504963000_55.9.571.16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0080"},{"key":"2025101710504963000_55.9.571.17","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. genetic\/familial high risk assessment: breast and ovarian version 1.2018. Fort Washington, PA: National Comprehensive Cancer Network, 2017."},{"key":"2025101710504963000_55.9.571.18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025101710504963000_55.9.571.19","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2025101710504963000_55.9.571.20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","article-title":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper","volume":"146","author":"Randall","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.09.009"},{"key":"2025101710504963000_55.9.571.23","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025101710504963000_55.9.571.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.10.007"},{"key":"2025101710504963000_55.9.571.25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IGC.0000000000000907","article-title":"Genetics consultation rates following a diagnosis of high-grade serous ovarian carcinoma in the canadian province of ontario","volume":"27","author":"McGee","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"2025101710504963000_55.9.571.26","first-page":"493","article-title":"Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature","volume":"67","author":"Hoskins","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025101710504963000_55.9.571.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"2025101710504963000_55.9.571.28","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"2025101710504963000_55.9.571.29","unstructured":"Court US. Association for Molecular Pathology vs Myriad Genetics. In: Court USS, editor. 133 S. Ct. 2107, 2013."},{"key":"2025101710504963000_55.9.571.30","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s10897-017-0099-2","article-title":"Cancer genetic counseling and testing in an era of rapid change","volume":"26","author":"Hooker","year":"2017","journal-title":"J Genet Couns"},{"key":"2025101710504963000_55.9.571.31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10689-015-9817-9","article-title":"Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines","volume":"14","author":"Marcus","year":"2015","journal-title":"Fam Cancer"},{"key":"2025101710504963000_55.9.571.32","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-014-9714-7"},{"key":"2025101710504963000_55.9.571.33","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.40"},{"key":"2025101710504963000_55.9.571.34","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-012-9547-1"},{"key":"2025101710504963000_55.9.571.35","unstructured":"United States Food and Drug Administration. FDA approves olaparib for germline BRCA-mutated metastatic breast cancer, 2018. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm592357.htm"},{"key":"2025101710504963000_55.9.571.36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2015.03.057","article-title":"The sooner the better: Genetic testing following ovarian cancer diagnosis","volume":"137","author":"Fox","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","article-title":"Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics","volume":"145","author":"Kentwell","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.38","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"key":"2025101710504963000_55.9.571.39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ejhg.2015.196","article-title":"BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study","volume":"24","author":"H\u00f8berg-Vetti","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2025101710504963000_55.9.571.40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10897-016-0064-5","article-title":"Large, prospective analysis of the reasons patients do not pursue brca genetic testing following genetic counseling","volume":"26","author":"Hayden","year":"2017","journal-title":"J Genet Couns"},{"key":"2025101710504963000_55.9.571.41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1188\/13.ONF.40-03AP","article-title":"Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing","volume":"40","author":"Gleeson","year":"2013","journal-title":"Oncol Nurs Forum"},{"key":"2025101710504963000_55.9.571.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4153-8","article-title":"A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention","volume":"18","author":"Hanley","year":"2018","journal-title":"BMC Cancer"},{"key":"2025101710504963000_55.9.571.43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10897-013-9664-5","article-title":"The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review","volume":"23","author":"Eichmeyer","year":"2014","journal-title":"J Genet Couns"},{"key":"2025101710504963000_55.9.571.44","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/IGC.0000000000000689","article-title":"Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing","volume":"26","author":"Cohen","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"2025101710504963000_55.9.571.45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2017.07.141","article-title":"Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care","volume":"147","author":"Senter","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.46","first-page":"143","article-title":"More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling","volume":"13","author":"Sie","year":"2014","journal-title":"Fam Cancer"},{"key":"2025101710504963000_55.9.571.47","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6874-12-12","article-title":"DNA-testing for BRCA1\/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct","volume":"12","author":"Sie","year":"2012","journal-title":"BMC Womens Health"},{"key":"2025101710504963000_55.9.571.48","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-013-9588-0"},{"key":"2025101710504963000_55.9.571.49","unstructured":"Martel L , Chagnon J . Canada\u2019s rural population since 1851: Statistics Canada."},{"key":"2025101710504963000_55.9.571.50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ygyno.2017.05.037","article-title":"A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment","volume":"146","author":"Bednar","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2025101710504963000_55.9.571.51","doi-asserted-by":"crossref","first-page":"djv351","DOI":"10.1093\/jnci\/djv351","article-title":"Germline findings in tumor-only sequencing: points to consider for clinicians and laboratories","volume":"108","author":"Raymond","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025101710504963000_55.9.571.52","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181837246"},{"key":"2025101710504963000_55.9.571.53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fgene.2017.00128","article-title":"Breast cancer risk estimation and personal insurance: a qualitative study presenting perspectives from canadian patients and decision makers","volume":"8","author":"Dalp\u00e9","year":"2017","journal-title":"Front Genet"},{"key":"2025101710504963000_55.9.571.54","unstructured":"Canlii. Genetic non-discrimination act, SC 2017, c 3. http:\/\/canlii.ca\/t\/52xqn"},{"key":"2025101710504963000_55.9.571.55","unstructured":"EEOC. The genetic information nondiscrimination act of 2008. https:\/\/www.eeoc.gov\/laws\/statues\/gina.cfm"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2018-105472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:51:00Z","timestamp":1760723460000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2018-105472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,8,22]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1136\/jmedgenet-2018-105472"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2018-105472","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]}}}